AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 159 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $61,078,571 | -13.5% | 2,467,821 | -1.0% | 0.01% | -12.5% |
| Q2 2023 | $70,601,052 | +156.5% | 2,492,975 | +108.0% | 0.01% | +166.7% |
| Q1 2023 | $27,530,000 | +82786.7% | 1,198,513 | +1.3% | 0.00% | -25.0% |
| Q4 2022 | $33,214 | -99.9% | 1,182,825 | -20.4% | 0.00% | -33.3% |
| Q3 2022 | $42,041,000 | +34.5% | 1,486,595 | +5.5% | 0.01% | +50.0% |
| Q2 2022 | $31,253,000 | -67.2% | 1,409,736 | -57.0% | 0.00% | -63.6% |
| Q1 2022 | $95,345,000 | -6.4% | 3,275,392 | +5.6% | 0.01% | -8.3% |
| Q4 2021 | $101,911,000 | -48.0% | 3,100,410 | -26.9% | 0.01% | -50.0% |
| Q3 2021 | $195,814,000 | -31.2% | 4,242,985 | -17.8% | 0.02% | -29.4% |
| Q2 2021 | $284,495,000 | +63.6% | 5,162,311 | +53.3% | 0.03% | +47.8% |
| Q1 2021 | $173,904,000 | +92.2% | 3,367,628 | +61.3% | 0.02% | +76.9% |
| Q4 2020 | $90,463,000 | +61.6% | 2,087,763 | +28.3% | 0.01% | +44.4% |
| Q3 2020 | $55,983,000 | -34.3% | 1,627,399 | +2.1% | 0.01% | -43.8% |
| Q2 2020 | $85,206,000 | +82.1% | 1,593,239 | +20.8% | 0.02% | +45.5% |
| Q1 2020 | $46,802,000 | +2.9% | 1,319,085 | +38.5% | 0.01% | +37.5% |
| Q4 2019 | $45,492,000 | +85.3% | 952,736 | +25.7% | 0.01% | +60.0% |
| Q3 2019 | $24,557,000 | -34.3% | 757,926 | +0.7% | 0.01% | -28.6% |
| Q2 2019 | $37,390,000 | -44.3% | 752,765 | -24.3% | 0.01% | -50.0% |
| Q1 2019 | $67,087,000 | +62.5% | 994,764 | +11.1% | 0.01% | +40.0% |
| Q4 2018 | $41,283,000 | +31413.7% | 895,314 | +52441.9% | 0.01% | – |
| Q3 2018 | $131,000 | -9.0% | 1,704 | -0.1% | 0.00% | – |
| Q2 2018 | $144,000 | +26.3% | 1,705 | +22.7% | 0.00% | – |
| Q1 2018 | $114,000 | +28.1% | 1,390 | -10.9% | 0.00% | – |
| Q4 2017 | $89,000 | -6.3% | 1,560 | +6.1% | 0.00% | – |
| Q3 2017 | $95,000 | -30.7% | 1,470 | -44.8% | 0.00% | – |
| Q2 2017 | $137,000 | -84.4% | 2,661 | -82.3% | 0.00% | – |
| Q1 2017 | $878,000 | +37.4% | 15,021 | -2.0% | 0.00% | – |
| Q4 2016 | $639,000 | -84.3% | 15,328 | -80.1% | 0.00% | -100.0% |
| Q3 2016 | $4,071,000 | +214.6% | 77,095 | +149.6% | 0.00% | – |
| Q2 2016 | $1,294,000 | +441.4% | 30,882 | +425.5% | 0.00% | – |
| Q1 2016 | $239,000 | -42.0% | 5,877 | -7.5% | 0.00% | – |
| Q4 2015 | $412,000 | -85.2% | 6,351 | -83.9% | 0.00% | -100.0% |
| Q3 2015 | $2,780,000 | -84.6% | 39,382 | -75.7% | 0.00% | -75.0% |
| Q2 2015 | $18,000,000 | -5.3% | 161,952 | -19.6% | 0.00% | 0.0% |
| Q1 2015 | $19,005,000 | -10.6% | 201,548 | +6.2% | 0.00% | -20.0% |
| Q4 2014 | $21,267,000 | +142.5% | 189,820 | +32.8% | 0.01% | +150.0% |
| Q3 2014 | $8,771,000 | +32.9% | 142,970 | -0.8% | 0.00% | 0.0% |
| Q2 2014 | $6,602,000 | +7.9% | 144,095 | -7.8% | 0.00% | 0.0% |
| Q1 2014 | $6,120,000 | +691.7% | 156,325 | +384.5% | 0.00% | – |
| Q4 2013 | $773,000 | -9.9% | 32,266 | +5.2% | 0.00% | – |
| Q3 2013 | $858,000 | – | 30,675 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |